Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Linker

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Neurological Disorders|June 18, 2019
Clinical trials in multiple sclerosis: potential future trial designsNavid Manouchehri, Yinan Zhang, Amber Salter, et al.
Frontiers in Immunology|October 14, 2022
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guideBart Van Wijmeersch, Hans-Peter Hartung, Patrick Vermersch, et al.
Plos One|November 19, 2010
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosisSebastian Doerck, Kerstin Göbel, Gesa Weise, et al.
Transplantation and Cellular Therapy|January 2, 2026
Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in the CNSAlexander Denk, Daniel Wolff, Matthias A Fante, et al.
Neurochemistry International|August 14, 2010
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes virusesJohann Sellner, Sabine Cepok, Sudhakar Reddy Kalluri, et al.
BMC Neurology|July 14, 2016
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumabTjalf Ziemssen, Achim Gass, Jens Wuerfel, et al.
Neuro-Oncology Advances|August 22, 2025
MRI-defined patterns of infiltration and outcome in patients with glioblastomaKatrin Scheu, Edith Vandieken, Katharina Hense, et al.
Neuro-Oncology Advances|November 4, 2024
Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort studyLinda Götz, Tananeh Ansafi, Michael Gerken, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
Frontiers in Immunology|November 3, 2022
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inMaura Pugliatti, Hans-Peter Hartung, Celia Oreja-Guevara, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Neurological Disorders|June 18, 2019
Clinical trials in multiple sclerosis: potential future trial designsNavid Manouchehri, Yinan Zhang, Amber Salter, et al.
Frontiers in Immunology|October 14, 2022
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guideBart Van Wijmeersch, Hans-Peter Hartung, Patrick Vermersch, et al.
Plos One|November 19, 2010
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosisSebastian Doerck, Kerstin Göbel, Gesa Weise, et al.
Transplantation and Cellular Therapy|January 2, 2026
Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in the CNSAlexander Denk, Daniel Wolff, Matthias A Fante, et al.
Neurochemistry International|August 14, 2010
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes virusesJohann Sellner, Sabine Cepok, Sudhakar Reddy Kalluri, et al.
BMC Neurology|July 14, 2016
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumabTjalf Ziemssen, Achim Gass, Jens Wuerfel, et al.
Neuro-Oncology Advances|August 22, 2025
MRI-defined patterns of infiltration and outcome in patients with glioblastomaKatrin Scheu, Edith Vandieken, Katharina Hense, et al.
Neuro-Oncology Advances|November 4, 2024
Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort studyLinda Götz, Tananeh Ansafi, Michael Gerken, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosisJohn Kramer, Ralf Linker, David Paling, et al.
Frontiers in Immunology|November 3, 2022
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inMaura Pugliatti, Hans-Peter Hartung, Celia Oreja-Guevara, et al.
Pageof 5